The latest price target for Edgewise Therapeutics (NASDAQ:EWTX) was reported by Stifel on January 22, 2025. The analyst firm set a price target for $30.00 expecting EWTX to rise to within 12 months (a possible 10.78% upside). 21 analyst firms have reported ratings in the last year.

The latest analyst rating for Edgewise Therapeutics (NASDAQ:EWTX) was provided by Stifel, and Edgewise Therapeutics initiated their hold rating.

There is no last upgrade for Edgewise Therapeutics

The last downgrade for Edgewise Therapeutics Inc happened on August 25, 2022 when Goldman Sachs changed their price target from N/A to $5 for Edgewise Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Edgewise Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Edgewise Therapeutics was filed on January 22, 2025 so you should expect the next rating to be made available sometime around January 22, 2026.

While ratings are subjective and will change, the latest Edgewise Therapeutics (EWTX) rating was a initiated with a price target of $0.00 to $30.00. The current price Edgewise Therapeutics (EWTX) is trading at is $27.08, which is within the analyst’s predicted range.